These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34624333)

  • 1. Hepatic lysosomal acid lipase overexpression worsens hepatic inflammation in mice fed a Western diet.
    Lopresti MW; Cui W; Abernathy BE; Fredrickson G; Barrow F; Desai AS; Revelo XS; Mashek DG
    J Lipid Res; 2021; 62():100133. PubMed ID: 34624333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic lysosomal acid lipase drives the autophagy-lysosomal response and alleviates cholesterol metabolic disorder in ApoE deficient mice.
    Li F; Zhao X; Li H; Liu Y; Zhang Y; Huang X; Cao J; Du F; Wu D; Yu H
    Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Dec; 1866(12):159027. PubMed ID: 34416392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic changes and propensity for inflammation, fibrosis, and cancer in livers of mice lacking lysosomal acid lipase.
    Bradić I; Liesinger L; Kuentzel KB; Vujić N; Trauner M; Birner-Gruenberger R; Kratky D
    J Lipid Res; 2023 Sep; 64(9):100427. PubMed ID: 37595802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocyte-specific deletion of lysosomal acid lipase leads to cholesteryl ester but not triglyceride or retinyl ester accumulation.
    Pajed L; Wagner C; Taschler U; Schreiber R; Kolleritsch S; Fawzy N; Pototschnig I; Schoiswohl G; Pusch LM; Wieser BI; Vesely P; Hoefler G; Eichmann TO; Zimmermann R; Lass A
    J Biol Chem; 2019 Jun; 294(23):9118-9133. PubMed ID: 31023823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte-specific lysosomal acid lipase deficiency protects mice from diet-induced obesity but promotes hepatic inflammation.
    Leopold C; Duta-Mare M; Sachdev V; Goeritzer M; Maresch LK; Kolb D; Reicher H; Wagner B; Stojakovic T; Ruelicke T; Haemmerle G; Hoefler G; Sattler W; Kratky D
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Apr; 1864(4):500-511. PubMed ID: 30639734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance.
    Thelwall PE; Smith FE; Leavitt MC; Canty D; Hu W; Hollingsworth KG; Thoma C; Trenell MI; Taylor R; Rutkowski JV; Blamire AM; Quinn AG
    J Hepatol; 2013 Sep; 59(3):543-9. PubMed ID: 23624251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and histological traits of reduced lysosomal acid lipase activity in the fatty liver.
    Carotti S; Lettieri-Barbato D; Piemonte F; Ruggiero S; Rosina M; Zalfa F; Zingariello M; Arciprete F; Valentini F; Francesconi M; D'Amico J; De Vincentis A; Baiocchini A; Perrone G; Antonelli-Incalzi R; Morini S; Picardi A; Aquilano K; Vespasiani-Gentilucci U
    Cell Death Dis; 2021 Nov; 12(12):1092. PubMed ID: 34795230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase.
    Carotti S; Aquilano K; Valentini F; Ruggiero S; Alletto F; Morini S; Picardi A; Antonelli-Incalzi R; Lettieri-Barbato D; Vespasiani-Gentilucci U
    Am J Physiol Gastrointest Liver Physiol; 2020 Oct; 319(4):G469-G480. PubMed ID: 32812776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic entrapment of esterified cholesterol drives continual expansion of whole body sterol pool in lysosomal acid lipase-deficient mice.
    Aqul A; Lopez AM; Posey KS; Taylor AM; Repa JJ; Burns DK; Turley SD
    Am J Physiol Gastrointest Liver Physiol; 2014 Oct; 307(8):G836-47. PubMed ID: 25147230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: A rare condition that mimics NAFLD.
    Carter A; Brackley SM; Gao J; Mann JP
    J Hepatol; 2019 Jan; 70(1):142-150. PubMed ID: 30315827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe markedly attenuates hepatic cholesterol accumulation and improves liver function in the lysosomal acid lipase-deficient mouse, a model for cholesteryl ester storage disease.
    Chuang JC; Lopez AM; Posey KS; Turley SD
    Biochem Biophys Res Commun; 2014 Jan; 443(3):1073-7. PubMed ID: 24370824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a common missense variant in LIPA gene on fatty liver disease and lipid phenotype: New perspectives from a single-center observational study.
    Pasta A; Borro P; Cremonini AL; Formisano E; Tozzi G; Cecchi S; Fresa R; Labanca S; Djahandideh A; Sukkar SG; Picciotto A; Pisciotta L
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00820. PubMed ID: 34476902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures.
    Gomaraschi M; Fracanzani AL; Dongiovanni P; Pavanello C; Giorgio E; Da Dalt L; Norata GD; Calabresi L; Consonni D; Lombardi R; Branchi A; Fargion S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Dec; 1864(12):158523. PubMed ID: 31505261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRD125, a potent and selective inhibitor of sterol O-acyltransferase 2 markedly reduces hepatic cholesteryl ester accumulation and improves liver function in lysosomal acid lipase-deficient mice.
    Lopez AM; Chuang JC; Posey KS; Ohshiro T; Tomoda H; Rudel LL; Turley SD
    J Pharmacol Exp Ther; 2015 Nov; 355(2):159-67. PubMed ID: 26283692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte-Specific Expression of Human Lysosome Acid Lipase Corrects Liver Inflammation and Tumor Metastasis in lal(-/-) Mice.
    Du H; Zhao T; Ding X; Yan C
    Am J Pathol; 2015 Sep; 185(9):2379-89. PubMed ID: 26212911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of sterol O-acyltransferase 2 (SOAT2) function in mice deficient in lysosomal acid lipase (LAL) dramatically reduces esterified cholesterol sequestration in the small intestine and liver.
    Lopez AM; Posey KS; Turley SD
    Biochem Biophys Res Commun; 2014 Nov; 454(1):162-6. PubMed ID: 25450374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing Cardiovascular Risk in Lysosomal Acid Lipase Deficiency.
    Maciejko JJ
    Am J Cardiovasc Drugs; 2017 Jun; 17(3):217-231. PubMed ID: 28197978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunity-related GTPase induces lipophagy to prevent excess hepatic lipid accumulation.
    Schwerbel K; Kamitz A; Krahmer N; Hallahan N; Jähnert M; Gottmann P; Lebek S; Schallschmidt T; Arends D; Schumacher F; Kleuser B; Haltenhof T; Heyd F; Gancheva S; Broman KW; Roden M; Joost HG; Chadt A; Al-Hasani H; Vogel H; Jonas W; Schürmann A
    J Hepatol; 2020 Oct; 73(4):771-782. PubMed ID: 32376415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate Treadmill Exercise Alleviates NAFLD by Regulating the Biogenesis and Autophagy of Lipid Droplet.
    Yang Y; Li X; Liu Z; Ruan X; Wang H; Zhang Q; Cao L; Song L; Chen Y; Sun Y
    Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of loss of SOAT2 function on disease progression in the lysosomal acid lipase-deficient mouse.
    Lopez AM; Chuang JC; Turley SD
    Steroids; 2018 Feb; 130():7-14. PubMed ID: 29246491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.